Last reviewed · How we verify
antidepressant medications, flexible drug choice
antidepressant medications, flexible drug choice is a Selective serotonin reuptake inhibitor (SSRI) Small molecule drug developed by Sir Mortimer B. Davis - Jewish General Hospital. It is currently in Phase 3 development for Major depressive disorder, Generalized anxiety disorder.
This antidepressant medication works by increasing the levels of certain neurotransmitters in the brain.
This antidepressant medication works by increasing the levels of certain neurotransmitters in the brain. Used for Major depressive disorder, Generalized anxiety disorder.
At a glance
| Generic name | antidepressant medications, flexible drug choice |
|---|---|
| Sponsor | Sir Mortimer B. Davis - Jewish General Hospital |
| Drug class | Selective serotonin reuptake inhibitor (SSRI) |
| Target | Serotonin transporter |
| Modality | Small molecule |
| Therapeutic area | Psychiatry |
| Phase | Phase 3 |
Mechanism of action
It does this by inhibiting the reuptake of serotonin and norepinephrine, allowing them to remain in the synaptic cleft for a longer period and increasing their availability for binding to postsynaptic receptors.
Approved indications
- Major depressive disorder
- Generalized anxiety disorder
Common side effects
- Nausea
- Headache
- Dizziness
- Insomnia
- Fatigue
Key clinical trials
- A Study to Evaluate the Efficacy, Pharmacokinetics, Safety and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression (PHASE3)
- A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression (PHASE3)
- A Study to Evaluate the Efficacy, Safety, and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression (PHASE3)
- A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression (PHASE3)
- A Study to Evaluate the Efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Participants With Treatment-resistant Depression (PHASE3)
- A Study of Esketamine Nasal Spray Plus a New Standard-of-care Oral Antidepressant or Placebo Nasal Spray Plus a New Standard-of-care Oral Antidepressant in Adult and Elderly Participants With Treatment-resistant Depression (PHASE3)
- eIMPACT-DM Pilot Trial: Depression Treatment to Reduce Diabetes Risk (PHASE2)
- eIMPACT Trial: Modernized Collaborative Care to Reduce the Excess CVD Risk of Older Depressed Patients (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- antidepressant medications, flexible drug choice CI brief — competitive landscape report
- antidepressant medications, flexible drug choice updates RSS · CI watch RSS
- Sir Mortimer B. Davis - Jewish General Hospital portfolio CI
Frequently asked questions about antidepressant medications, flexible drug choice
What is antidepressant medications, flexible drug choice?
How does antidepressant medications, flexible drug choice work?
What is antidepressant medications, flexible drug choice used for?
Who makes antidepressant medications, flexible drug choice?
What drug class is antidepressant medications, flexible drug choice in?
What development phase is antidepressant medications, flexible drug choice in?
What are the side effects of antidepressant medications, flexible drug choice?
What does antidepressant medications, flexible drug choice target?
Related
- Drug class: All Selective serotonin reuptake inhibitor (SSRI) drugs
- Target: All drugs targeting Serotonin transporter
- Manufacturer: Sir Mortimer B. Davis - Jewish General Hospital — full pipeline
- Therapeutic area: All drugs in Psychiatry
- Indication: Drugs for Major depressive disorder
- Indication: Drugs for Generalized anxiety disorder
- Compare: antidepressant medications, flexible drug choice vs similar drugs
- Pricing: antidepressant medications, flexible drug choice cost, discount & access